Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

Dearden, 2013, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Ann Oncol, 24, 2371, 10.1093/annonc/mdt205 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539 Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316 Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906 Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478 Khozin, 2015, FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer, Clin Cancer Res, 21, 2436, 10.1158/1078-0432.CCR-14-3157 Novartis. Novartis lung cancer drug Zykadia gains EU approval, providing new therapy for certain patients with ALK+ NSCLC. https://www.novartis.com/news/media-releases/novartis-lung-cancer-drug-zykadia%C2%AE-gains-eu-approval-providing-new-therapy. Accessed June 1, 2017. Kim, 2016, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, 17, 452, 10.1016/S1470-2045(15)00614-2 Mok, 2015, ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ), J Clin Oncol, 33, 8059, 10.1200/jco.2015.33.15_suppl.8059 U.S. Food and Drug Administration. FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm. Accessed June 1, 2017. Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X Seto, 2013, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study, Lancet Oncol, 14, 590, 10.1016/S1470-2045(13)70142-6 Gadgeel, 2014, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, 15, 1119, 10.1016/S1470-2045(14)70362-6 Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X Tamura, 2017, Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP, J Clin Oncol, 35, 1515, 10.1200/JCO.2016.70.5749 U.S. Food and Drug Administration. FDA approves new oral therapy to treat ALK-positive lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm. Accessed March 9, 2017. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer [e-pub ahead of print]. N Engl J Med. http://dx.doi.org/10.1056/NEJMoa1704795, accessed July 19, 2017. Hsu, 2016, Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population, J Clin Oncol, 34, e20598, 10.1200/JCO.2016.34.15_suppl.e20598 Kim, 2016, Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): first report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA), J Clin Oncol, 34, 9007, 10.1200/JCO.2016.34.15_suppl.9007 Gadgeel, 2016, Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer, J Clin Oncol, 34, 4079, 10.1200/JCO.2016.68.4639 Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial, Lancet, 390, 29, 10.1016/S0140-6736(17)30565-2